<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05012436</url>
  </required_header>
  <id_info>
    <org_study_id>YHD1119-107</org_study_id>
    <nct_id>NCT05012436</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Pharmacokinetics and Safety of YHD1119 in Subjects With Renal Impairment and Healthy Subjects</brief_title>
  <official_title>A Study to Evaluate the Pharmacokinetics and Safety Following a Single Oral Dose of YHD1119 in Subjects With Renal Impairment and Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yuhan Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yuhan Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to compare the pharmacokinetic characteristics and safety of&#xD;
      YHD1119(Pregabalin SR 75mg) and YHD1119(Pregabalin SR 150mg) in subjects with renal&#xD;
      impairment and healthy subjects. YHD1119 is sustained-release (SR) formulation which is made&#xD;
      by Yuhan Corporation. Primary endpoints are Cmax and AUClast and secondary endpoints are&#xD;
      AUCinf,Tmax, t1/2, CL/F and V/F.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 24, 2021</start_date>
  <completion_date type="Anticipated">January 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>0,1,2,3,4,5,6,8,10,12,14,24,48,72 hour</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUClast</measure>
    <time_frame>0,1,2,3,4,5,6,8,10,12,14,24,48,72 hour</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUCinf</measure>
    <time_frame>0,1,2,3,4,5,6,8,10,12,14,24,48,72 hour</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>0,1,2,3,4,5,6,8,10,12,14,24,48,72 hour</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2</measure>
    <time_frame>0,1,2,3,4,5,6,8,10,12,14,24,48,72hour</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F</measure>
    <time_frame>0,1,2,3,4,5,6,8,10,12,14,24,48,72 hour</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>V/F</measure>
    <time_frame>0,1,2,3,4,5,6,8,10,12,14,24,48,72 hour</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Healthy Volunteer</condition>
  <condition>Renal Impairments</condition>
  <arm_group>
    <arm_group_label>YHD1119 75mg, 150mg NF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CLcr (mL/min/1.73m2) &gt;= 60 Period 1 : YHD1119 75 mg Period 2 : YHD1119 150 mg NF</description>
  </arm_group>
  <arm_group>
    <arm_group_label>YHD1119 75mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60 &gt; CLcr (mL/min/1.73m2) &gt;= 30 Period 1 : YHD1119 75 mg Period 2 : NA</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YHD1119 75mg</intervention_name>
    <description>A single oral dose</description>
    <arm_group_label>YHD1119 75mg</arm_group_label>
    <arm_group_label>YHD1119 75mg, 150mg NF</arm_group_label>
    <other_name>YHD1119 150mg NF</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  19~75 years old, healthy volunteers and renal impairments&#xD;
&#xD;
          -  eGFR &gt;= 60mL/min/1.73m2&#xD;
&#xD;
          -  60 mL/min/1.73m2 &gt; eGFR &gt;= 30mL/min/1.73m2&#xD;
&#xD;
          -  written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  AST or ALT &gt; 1.5 * Upper normal range&#xD;
&#xD;
          -  Total bilirubin &gt; 1.5 * Upper normal range&#xD;
&#xD;
          -  Blood CPK &gt; 1.5 * Upper normal range&#xD;
&#xD;
          -  Total Cholesterol &gt;1.5 * Upper normal range&#xD;
&#xD;
          -  Woman who is pregnant or lactating&#xD;
&#xD;
          -  Patients who are difficult to participate in cinical trials judged by Investigators&#xD;
&#xD;
          -  have participated in other clinical trials within 180 days before IP intake&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>SeungHoon Han</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Catholic University of Korea</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hyounggyoon Yoo</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHA University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Seonmi Kang</last_name>
    <phone>8228280565</phone>
    <email>smkang@yuhan.co.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHA Bundang Medical Center, CHA University</name>
      <address>
        <city>Gyeonggi-do</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyounggyoon Yoo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea, Seoul St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Seunghoon Han</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 27, 2021</study_first_submitted>
  <study_first_submitted_qc>August 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 19, 2021</study_first_posted>
  <last_update_submitted>August 12, 2021</last_update_submitted>
  <last_update_submitted_qc>August 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

